OBJECTIVE: To test the hypothesis that restoration of antithrombin plasma concentrations attenuates vascular leakage by inhibiting neutrophil activation through syndecan-4 receptor inhibition in an established ovine model of acute lung injury. DESIGN: Randomized controlled laboratory experiment. SETTING: University animal research facility. SUBJECTS:Eighteen chronically instrumented sheep. INTERVENTIONS:Following combined burn and smoke inhalation injury (40% of total body surface area, third-degree flame burn; 4 × 12 breaths of cold cotton smoke), chronically instrumented sheep were randomly assigned to receive an IV infusion of 6 IU/kg/hr recombinant human antithrombin III or normal saline (n = 6 each) during the 48-hour study period. In addition, six sham animals (not injured, continuous infusion of vehicle) were used to obtain reference values for histological and immunohistochemical analyses. MEASUREMENTS AND MAIN RESULTS: Compared to control animals, recombinant human antithrombin III reduced the number of neutrophils per hour in the pulmonary lymph (p < 0.01 at 24 and 48 hr), alveolar neutrophil infiltration (p = 0.04), and pulmonary myeloperoxidase activity (p = 0.026). Flow cytometric analysis revealed a significant reduction of syndecan-4-positive neutrophils (p = 0.002 vs control at 24 hr). Treatment with recombinant human antithrombin III resulted in a reduction of pulmonary nitrosative stress (p = 0.002), airway obstruction (bronchi: p = 0.001, bronchioli: p = 0.013), parenchymal edema (p = 0.044), and lung bloodless wet-to-dry-weight ratio (p = 0.015). Clinically, recombinant human antithrombin III attenuated the increased pulmonary transvascular fluid flux (12-48 hr: p ≤ 0.001 vs control each) and the deteriorated pulmonary gas exchange (12-48 hr: p < 0.05 vs control each) without increasing the risk of bleeding. CONCLUSIONS: The present study provides evidence for the interaction between antithrombin and neutrophils in vivo, its pathophysiological role in vascular leakage, and the therapeutic potential of recombinant human antithrombin III in a large animal model of acute lung injury.
RCT Entities:
OBJECTIVE: To test the hypothesis that restoration of antithrombin plasma concentrations attenuates vascular leakage by inhibiting neutrophil activation through syndecan-4 receptor inhibition in an established ovine model of acute lung injury. DESIGN: Randomized controlled laboratory experiment. SETTING: University animal research facility. SUBJECTS: Eighteen chronically instrumented sheep. INTERVENTIONS: Following combined burn and smoke inhalation injury (40% of total body surface area, third-degree flame burn; 4 × 12 breaths of cold cotton smoke), chronically instrumented sheep were randomly assigned to receive an IV infusion of 6 IU/kg/hr recombinant humanantithrombin III or normal saline (n = 6 each) during the 48-hour study period. In addition, six sham animals (not injured, continuous infusion of vehicle) were used to obtain reference values for histological and immunohistochemical analyses. MEASUREMENTS AND MAIN RESULTS: Compared to control animals, recombinant humanantithrombin III reduced the number of neutrophils per hour in the pulmonary lymph (p < 0.01 at 24 and 48 hr), alveolar neutrophil infiltration (p = 0.04), and pulmonary myeloperoxidase activity (p = 0.026). Flow cytometric analysis revealed a significant reduction of syndecan-4-positive neutrophils (p = 0.002 vs control at 24 hr). Treatment with recombinant humanantithrombin III resulted in a reduction of pulmonary nitrosative stress (p = 0.002), airway obstruction (bronchi: p = 0.001, bronchioli: p = 0.013), parenchymal edema (p = 0.044), and lung bloodless wet-to-dry-weight ratio (p = 0.015). Clinically, recombinant humanantithrombin III attenuated the increased pulmonary transvascular fluid flux (12-48 hr: p ≤ 0.001 vs control each) and the deteriorated pulmonary gas exchange (12-48 hr: p < 0.05 vs control each) without increasing the risk of bleeding. CONCLUSIONS: The present study provides evidence for the interaction between antithrombin and neutrophils in vivo, its pathophysiological role in vascular leakage, and the therapeutic potential of recombinant humanantithrombin III in a large animal model of acute lung injury.
Authors: S Dunzendorfer; N Kaneider; A Rabensteiner; C Meierhofer; C Reinisch; J Römisch; C J Wiedermann Journal: Blood Date: 2001-02-15 Impact factor: 22.113
Authors: Perenlei Enkhbaatar; Rhykka Connelly; Jianpu Wang; Yoshimitsu Nakano; Matthias Lange; Atsumori Hamahata; Eszter Horvath; Csaba Szabo; Stefan Jaroch; Peter Hölscher; Margrit Hillmann; Lillian D Traber; Frank C Schmalstieg; David N Herndon; Daniel L Traber Journal: Crit Care Med Date: 2009-01 Impact factor: 7.598
Authors: Sebastian Rehberg; Marc O Maybauer; Dirk M Maybauer; Lillian D Traber; Perenlei Enkhbaatar; Daniel L Traber Journal: Front Biosci (Schol Ed) Date: 2010-01-01
Authors: Guillermo Foncerrada; Derek M Culnan; Karel D Capek; Sagrario González-Trejo; Janos Cambiaso-Daniel; Lee C Woodson; David N Herndon; Celeste C Finnerty; Jong O Lee Journal: Ann Plast Surg Date: 2018-03 Impact factor: 1.539
Authors: Sebastian Rehberg; Yusuke Yamamoto; Linda E Sousse; Collette Jonkam; Robert A Cox; Donald S Prough; Perenlei Enkhbaatar Journal: J Trauma Acute Care Surg Date: 2014-01 Impact factor: 3.313
Authors: Sven Asmussen; Hiroshi Ito; Daniel L Traber; Jae W Lee; Robert A Cox; Hal K Hawkins; Daniel F McAuley; David H McKenna; Lillian D Traber; Hanjing Zhuo; Jennifer Wilson; David N Herndon; Donald S Prough; Kathleen D Liu; Michael A Matthay; Perenlei Enkhbaatar Journal: Thorax Date: 2014-06-02 Impact factor: 9.139
Authors: Mohamed ElSaadani; Syed M Ahmed; Christina Jacovides; Alfonso Lopez; Victoria E Johnson; Lewis J Kaplan; C William Schwab; Douglas H Smith; Jose L Pascual Journal: J Trauma Acute Care Surg Date: 2021-02-01 Impact factor: 3.313